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Silodosin is one of the a1-adrenergic receptor antagonists and is
commonly used to treat male lower urinary tract symptoms due to
benign prostatic hypertrophy.1 The incidence of silodosin-related
adverse events was 69.7%,1 and themost common adverse event af-
ter silodosin treatment was abnormal ejaculation.1 However, to our
knowledge, there has been no case report on cutaneous drug erup-
tion caused by silodosin in English literature. Herein, we report the
ﬁrst case of silodosin-induced drug eruption.
A 58-year-old male, who had suffered from benign prostatic hy-
pertrophy for 5 years, developed his erythematous plaques andwas
referred to our department for evaluation of his eruption. Physical
examination revealed that papules and erythematous eruption had
developed on his trunk (Fig. 1AeC) and extremities without
mucosal involvement after the 3rd administration of silodosin for
his benign prostatic hypertrophy. Laboratory and biochemical ex-
aminations were within normal ranges. At the ﬁrst visit, a skin bi-
opsy specimen taken from an erythematous lesion on his trunk
revealed lymphocyte inﬁltration around vessels in dermis
(Fig. 1D) with less epidermal change. We performed lymphocyte
stimulation test (LST) with silodosin as described previously.2,3Peer review under responsibility of Japanese Society of Allergology.
http://dx.doi.org/10.1016/j.alit.2015.11.008
1323-8930/Copyright © 2015, Japanese Society of Allergology. Production and hosting by Else
licenses/by-nc-nd/4.0/).3H-thymidine incorporation was signiﬁcantly increased by the
addition of 5.8  105 M silodosin (corresponding to Cmax) to
the peripheral lymphocyte culture with stimulation index of 4.3
(Fig. 1E). Based on the clinical course and laboratory examination,
we diagnosed silodosin-induced maculopapular type drug erup-
tion. The patient was treated with oral methyl prednisolone
10 mg per day and topical betamethasone butyrate propionate
ointment. His eruption improved remarkably in a week, with resid-
ual pigmentation.
To our knowledge, this is the ﬁrst report of drug eruption caused
by silodosin. Because several cases of drug eruption due to other
a1-adrenergic receptor antagonists have been reported, we
reviewed the English and Japanese reported cases of drug eruption
caused by a1-adrenergic receptor antagonists.4e8 There have been
5 reported cases, excluding our case. Skin eruption types were as
follow; 2 cases of photo-allergic type, 1 cases of lichen planus
type,1 case of toxic epidermal necrolysis, and 1 case of psoriasiform
type. Although our case is relatively mild form of drug eruption
with less epidermal change, 50% of case showed lichenoid tissue re-
action in epidermis. Therefore, it should be kept in mind that a se-
vere cutaneous drug eruption might occur after silodosin
administration.vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. (AeC) Clinical manifestation. (A) Lowmagniﬁcation view of clinical feature showing erythema and papules on his trunk. (B, C) High manifestation views of clinical feature on
(B) chest and (C) abdomen. (D) Histological examination. A skin biopsy specimen shows lymphocyte inﬁltration around vessels in dermis (hematoxylin and eosin; original magni-
ﬁcation, 25). (E) LST showing an elevation of 3H-thymidine (TdR) incorporation in response to silodosin added to the 72 h culture of patient's PBMC. Results are presented as the
mean ± SEM. P-value was obtained by student's t-test. *P < 0.05.
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